Dian Y - Search Results

1

Corrigendum to 'Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.' [EClinicalMedicine 59 (2023) 101981].

Sun Y, Jin L, Dian Y, Shen M, Zeng F, Chen X, Deng G. Sun Y, et al. Among authors: dian y. EClinicalMedicine. 2023 Jul 26;62:102110. doi: 10.1016/j.eclinm.2023.102110. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37560258 Free PMC article.

2

Elevated troponin levels predict the reduced efficacy of Paxlovid in COVID-19 patients.

Zhao D, He Y, Dian Y, Meng Y, Zeng F, Deng G. Zhao D, et al. Among authors: dian y. J Infect. 2023 Aug;87(2):148-150. doi: 10.1016/j.jinf.2023.03.026. Epub 2023 Apr 3. J Infect. 2023. PMID: 37019287 Free PMC article. No abstract available.

3

Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.

Deng G, Li D, Sun Y, Jin L, Zhou Q, Xiao C, Wu Q, Sun H, Dian Y, Zeng F, Pan P, Shen M. Deng G, et al. Among authors: dian y. J Med Virol. 2023 Apr;95(4):e28756. doi: 10.1002/jmv.28756. J Med Virol. 2023. PMID: 37185838

4

Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.

Sun Y, Jin L, Dian Y, Shen M, Zeng F, Chen X, Deng G. Sun Y, et al. Among authors: dian y. EClinicalMedicine. 2023 May 5;59:101981. doi: 10.1016/j.eclinm.2023.101981. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37193346 Free PMC article.

5

Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities.

Dian Y, Meng Y, Sun Y, Deng G, Zeng F. Dian Y, et al. J Infect. 2023 Aug;87(2):e24-e27. doi: 10.1016/j.jinf.2023.05.012. Epub 2023 May 17. J Infect. 2023. PMID: 37207823 Free PMC article. No abstract available.

6

Immunophenotyping characteristics and outcome of COVID-19 patients: peripheral blood CD8+T cell as a prognostic biomarker for patients with Nirmatrelvir.

Sun Y, Dian Y, Gao Q, Deng G. Sun Y, et al. Among authors: dian y. Front Immunol. 2023 Sep 20;14:1227905. doi: 10.3389/fimmu.2023.1227905. eCollection 2023. Front Immunol. 2023. PMID: 37799722 Free PMC article.

7

Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine.

Mao M, Dian Y, Sun Y, Chen W, Zhu W, Deng G. Mao M, et al. Among authors: dian y. Front Cell Infect Microbiol. 2023 Oct 18;13:1237277. doi: 10.3389/fcimb.2023.1237277. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37920449 Free PMC article.

8

Molecular landmarks of tumor disulfidptosis across cancer types to promote disulfidptosis-target therapy.

Zhao D, Meng Y, Dian Y, Zhou Q, Sun Y, Le J, Zeng F, Chen X, He Y, Deng G. Zhao D, et al. Among authors: dian y. Redox Biol. 2023 Dec;68:102966. doi: 10.1016/j.redox.2023.102966. Epub 2023 Nov 19. Redox Biol. 2023. PMID: 38035663 Free PMC article.

9

Association of eosinopenia with worsening prognosis in hospitalized Azvudine-treated COVID-19 patients: a retrospective cohort study.

Wang X, Dian Y, Zhou Q, Deng G, Wei R, Zeng F. Wang X, et al. Among authors: dian y. Front Immunol. 2023 Dec 15;14:1320973. doi: 10.3389/fimmu.2023.1320973. eCollection 2023. Front Immunol. 2023. PMID: 38162638 Free PMC article.

10

Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials.

Sun Y, Liu Y, Dian Y, Zeng F, Deng G, Lei S. Sun Y, et al. Among authors: dian y. Int J Surg. 2024 Aug 1;110(8):4688-4694. doi: 10.1097/JS9.0000000000001514. Int J Surg. 2024. PMID: 38701500 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters